Drug Repositioning Service Market Report 2026

The drug repositioning service market size has grown strongly in recent years. It will grow from $34.2 billion in 2025 to $36.19 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing pharmaceutical r&d costs, availability of extensive legacy drug data, rising number of failed clinical trials, growing demand for faster drug development cycles, early adoption of computational drug discovery.

The drug repositioning service market size is expected to see strong growth in the next few years. It will grow to $45.92 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing demand for cost-efficient drug development, rising adoption of ai-driven discovery tools, growing focus on rare and orphan diseases, expansion of data-driven clinical research, increasing regulatory acceptance of repurposed drugs. Major trends in the forecast period include increasing use of ai-based drug repurposing platforms, rising focus on failed clinical drug re-evaluation, growing integration of real-world evidence in drug discovery, expansion of precision medicine-oriented repositioning, enhanced collaboration between pharma and cros.

The increase in healthcare expenditures is expected to drive the growth of the drug repositioning service market in the coming years. Healthcare expenditures refer to the total funds allocated to health services, including prevention, treatment, rehabilitation, and administration. These expenditures are rising mainly due to higher medical costs fueled by technological advancements and growing demand for healthcare services. Increased healthcare spending benefits drug repositioning services, as more funding enables additional clinical trials and research, speeding up the discovery of new therapeutic applications for existing drugs. For example, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a notable increase of 5.6% in nominal terms from 2022 to 2023. Therefore, the rise in healthcare expenditures is contributing to the growth of the drug repositioning service market.

Major companies operating in the drug repositioning service market are emphasizing the use of artificial intelligence (AI) in drug repositioning, such as computational drug repositioning systems, which systematically identify new therapeutic uses for existing drugs through AI-driven analysis of literature and biological data. A computational drug repositioning system is a technology-based platform that utilizes artificial intelligence, machine learning, and data mining to systematically analyze existing drugs, compounds, and biological data. For example, in November 2024, UBE and FRONTEO, Japanese companies, initiated a co-creation project. The co-creation project provides a collaborative framework that combines expertise from both UBE and FRONTEO to advance drug repositioning efforts. It facilitates seamless interaction between dry research (data analysis) and wet research (biological testing), enhancing the transition from hypothesis generation to experimental validation. By leveraging FRONTEO’s AI-driven Drug Discovery AI Factory and KIBIT technology, the project systematically uncovers previously unreported relationships between diseases and molecules.

In January 2024, Cosmos Health Inc., a US-based healthcare group, acquired the Cloudscreen platform from Cloudpharm P.C. for an undisclosed amount. Through this acquisition, Cosmos Health Inc. aims to advance drug repurposing initiatives by utilizing Cloudscreen’s AI platform to identify new therapeutic applications for existing drugs more effectively. Cloudpharm P.C. is a Greece-based company that provides drug repositioning services.

Major companies operating in the drug repositioning service market are Recursion Pharmaceuticals Inc., Excelra, LifeArc, Cosmos Health Inc., Fios Genomics, Insilico Medicine Inc., Melior Discovery, Delta4, Acubiosys, VeriSIM Life, BioXcel Therapeutics Inc., Pharnext S.S., NuMedii, GVK Biosciences, Plex Research, Paradigm Biopharmaceuticals, BenevolentAI Limited.

North America was the largest region in the drug repositioning service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repositioning service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug repositioning service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the drug repositioning service market by increasing costs associated with imported computational infrastructure, specialized software licenses, laboratory reagents, and cross-border research services. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on global data platforms and outsourced research activities, while Asia-Pacific faces increased costs for collaborative research services. These tariffs are elevating overall project expenses and slowing multinational repositioning programs. However, they are also encouraging regional research partnerships, domestic service provider growth, and localized drug development strategies.

The drug repositioning service market research report is one of a series of new reports that provides drug repositioning service market statistics, including drug repositioning service industry global market size, regional shares, competitors with a drug repositioning service market share, detailed drug repositioning service market segments, market trends and opportunities, and any further data you may need to thrive in the drug repositioning service industry. This drug repositioning service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug repositioning service focuses on systematically discovering new therapeutic applications for existing drugs, enabling pharmaceutical companies to enhance the value of their current drug portfolios while reducing the risks linked to developing entirely new compounds. By utilizing existing clinical data and research, drug repositioning services help optimize the drug development process, considerably lowering the time and cost needed to deliver effective treatments to patients.

The main types of drug repositioning services include generic drugs and drugs that failed in clinical trials. Generic drugs are medications that contain the same active ingredients, strength, dosage form, and therapeutic effect as brand-name drugs but are generally available at lower costs. The therapeutic areas include oncology, neurology, infectious diseases, cardiovascular diseases, and other therapeutic areas. These are utilized by various end users, including pharmaceutical companies, biotechnology firms, contract research organizations (CROs), academic research institutions, hospitals, and ambulatory surgical centers.

The drug repositioning service market consists of revenues earned by entities by providing services such as target validation, pharmacovigilance support, formulation optimization, drug combination analysis, and post-marketing surveillance. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.